Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients

References

• Canti L, Arien KK, Desombere I, et al. Antibody response against SARS-CoV-2 Delta and omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell. 2022;40(4):335–337. doi:10.1016/j.ccell.2022.02.005
   PubMed Web of Science ®Google Scholar
• Shahzad M, Chaudhary SG, Zafar MU, et al. Impact of COVID-19 in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022;24(2):e13792.
   PubMed Web of Science ®Google Scholar
• Baud D, Qi X, Nielsen-Saines K, et al. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20(7):773. doi:10.1016/S1473-3099(20)30195-X
   PubMed Web of Science ®Google Scholar
• Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185–e193. doi:10.1016/S2352-3026(20)30429-4
   PubMed Web of Science ®Google Scholar
• Mushtaq MU, Shahzad M, Chaudhary SG, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients. Transplant Cell Ther. 2021;27(9):796 e1–796 e7.
   PubMedGoogle Scholar
• CDC.gov. Centers for Disease Control and Provention; [cited 2022 Mar 1]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home.
   Google Scholar
• Talekar MK, Olson T. Immune reconstitution after hematopoietic stem cell transplantation. In: Brown VI, ed. Hematopoietic stem cell transplantation for the pediatric hematologist/oncologist. 1st 2018. ed. Springer International Publishing, Hershey, Pennsylvania, USA; 2018. p. 371–383.
   Google Scholar
• Algwaiz G, Aljurf M, Koh M, et al. Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the worldwide network for blood and marrow transplantation and center for international blood and marrow transplant research health services and international studies committee. Biol Blood Marrow Transplant. 2020;26(12):2181–2189. doi:10.1016/j.bbmt.2020.07.021
   PubMed Web of Science ®Google Scholar
• Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Waghmare A, Abidi MZ, Boeckh M, et al. Guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy recipients. Biol Blood Marrow Transplant. 2020;26(11):1983–1994. doi:10.1016/j.bbmt.2020.07.027
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Recommendations of the National Comprehensive Cancer Network® (NCCN®) Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis [Internet]. Cited 2022]. Available from https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v7-0.pdf?sfvrsn=b483da2b_119.
   Google Scholar
• Kimura M, Ferreira VH, Kothari S, et al. Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients. Transplant Cell Ther. 2022;28(10):706.e1–706.e10. doi:10.1016/j.jtct.2022.07.024
   PubMedGoogle Scholar
• Ge C, Du K, Luo M, et al. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol. 2022;11(1):46. doi:10.1186/s40164-022-00299-6
   PubMed Web of Science ®Google Scholar
• Uyemura BS, Abid MA, Suelzer E, et al. Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen. Bone Marrow Transplant. 2022;57(11):1727–1731. doi:10.1038/s41409-022-01795-3
   PubMed Web of Science ®Google Scholar
• Khan QJ, Bivona CR, Martin GA, et al. Evaluation of the durability of the immune humoral response to COVID-19 vaccines in patients with cancer undergoing treatment or who received a stem cell transplant. JAMA Oncol. 2022;8(7):1053–1058. doi:10.1001/jamaoncol.2022.0752
   PubMed Web of Science ®Google Scholar
• NIH. Clinical Spectrum of SARS-CoV-2 Infection [Internet]. National Instituite of Health; c2020-2021 [Cited 2021]. Available from https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.
   Google Scholar
• Camargo JF, Mendoza MA, Lin R, et al. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy. Transpl Infect Dis. 2021;23(4):e13625. doi:10.1111/tid.13625
   PubMedGoogle Scholar
• Martinez JC, Sica RA, Stockerl-Goldstein K, et al. COVID-19 in patients with hematologic malignancies: outcomes and options for treatments. Acta Haematol. 2022;145(3):244–256. doi:10.1159/000522436
   PubMed Web of Science ®Google Scholar
• Varma A, Kosuri S, Ustun C, et al. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia. 2020;34(10):2809–2812. doi:10.1038/s41375-020-01019-x
   PubMed Web of Science ®Google Scholar
• Malard F, Genthon A, Brissot E, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55(11):2180–2184. doi:10.1038/s41409-020-0931-4
   PubMed Web of Science ®Google Scholar
• Agrawal N, Singh R, Sharma SK, et al. Outcomes of COVID-19 in hematopoietic stem cell transplant recipients: multicenter retrospective analysis. Indian J Hematol Blood Transfus. 2022;38(2):388–393. doi: 10.1007/s12288-021-01472-3
   PubMed Web of Science ®Google Scholar
• Altuntas F, Ata N, Yigenoglu TN, et al. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2021;56(4):952–955. doi:10.1038/s41409-020-01084-x
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892. doi:10.1182/blood.2020008824
   PubMed Web of Science ®Google Scholar
• Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi:10.1186/s13045-021-01177-0
   PubMed Web of Science ®Google Scholar
• Ourworldindata.org. [Internet] SARS-COV-2 sequences by variant. SARS-CoV-2 sequences by variant, Aug 15, 2022.2022 Cited Sep 11]. Available from: https://ourworldindata.org/grapher/covid-variants-bar?country=CAN∼BWA∼ESP∼ZAF∼AUS∼GBR∼USA∼DEU∼ITA∼BEL∼FRA.
   Google Scholar
• Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with Delta (B.1.617.2): retrospective cohort study. BMJ. 2022;378:e070695.
   PubMedGoogle Scholar
• Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of patients infected with Delta versus Omicron COVID-19 variants presenting to Paris emergency departments: a retrospective cohort study. Ann Intern Med. 2022;175(6):831–837. doi:10.7326/M22-0308
   PubMed Web of Science ®Google Scholar
• Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–1312. doi:10.1016/S0140-6736(22)00462-7
   PubMed Web of Science ®Google Scholar
• Wu X, Wang L, Shen L, et al. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients. J Hematol Oncol. 2022;15(1):81. doi:10.1186/s13045-022-01300-9
   PubMed Web of Science ®Google Scholar
• Abid MA, Abid MB. SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: a systematic review and preliminary observations. Hematol Oncol. 2022;40(2):287–291. doi:10.1002/hon.2957
   PubMed Web of Science ®Google Scholar
• Abid MB, Rubin M, Ledeboer N, et al. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022;40(4):340–342. doi:10.1016/j.ccell.2022.02.010
   PubMed Web of Science ®Google Scholar
• Sweeney C, Vyas P. The graft-versus-leukemia effect in AML. Front Oncol. 2019;9:1217. doi:10.3389/fonc.2019.01217
   PubMed Web of Science ®Google Scholar
• Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence. 2016;7(8):901–916. doi:10.1080/21505594.2016.1208866
   PubMed Web of Science ®Google Scholar
• Bachier CR, Aggarwal SK, Hennegan K, et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis. Transplant Cell Ther. 2021;27(6):504 e1–504 e6.
   PubMedGoogle Scholar
• Mushtaq MU, Nelson M, Bivona CR, et al. Immunogenicity of Sars-Cov-2 vaccination in hematopoietic stem cell transplant and chimeric antigen receptor T-Cell therapy recipients. Transplantation and Cellular Therapy. 2022;28(3):S46–S47. doi:10.1016/S2666-6367(22)00215-9
   Google Scholar
• DeFilipp Z, Alousi AM, Pidala JA, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the chronic GVHD consortium. Blood Adv. 2021;5(20):4278–4284. doi:10.1182/bloodadvances.2021004941
   PubMed Web of Science ®Google Scholar
• Sung AD, Chao NJ. Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med. 2013;2(1):25–32. doi:10.5966/sctm.2012-0115
   PubMed Web of Science ®Google Scholar
• Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34(5):1229–1240. doi:10.1038/s41375-020-0804-2
   PubMed Web of Science ®Google Scholar
• Saidu NEB, Bonini C, Dickinson A, et al. New approaches for the treatment of chronic Graft-Versus-Host disease: current status and future directions. Front Immunol. 2020;11:578314. doi:10.3389/fimmu.2020.578314
   PubMed Web of Science ®Google Scholar
• Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological injury. Nat Rev Immunol. 2021;21(5):277–291. doi:10.1038/s41577-020-00457-z
   PubMed Web of Science ®Google Scholar
• Walti CS, Krantz EM, Maalouf J, et al. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight. 2021;6(11):06. doi:10.1172/jci.insight.146743
   Web of Science ®Google Scholar
• Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925–935. doi:10.1182/blood.2019004000
   PubMed Web of Science ®Google Scholar
• Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. doi:10.1186/s12916-020-01817-1
   PubMed Web of Science ®Google Scholar
• Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8(8):e583–e592. doi:10.1016/S2352-3026(21)00169-1
   PubMed Web of Science ®Google Scholar
• Dhakal B, Abedin S, Fenske T, et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021;138(14):1278–1281. doi:10.1182/blood.2021012769
   PubMed Web of Science ®Google Scholar
• Redjoul R, Le Bouter A, Beckerich F, et al. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398(10297):298–299. doi:10.1016/S0140-6736(21)01594-4
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885–2894. doi:10.1038/s41375-021-01302-5
   PubMed Web of Science ®Google Scholar
• Shem-Tov N, Yerushalmi R, Danylesko I, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol. 2022;196(4):884–891. doi:10.1111/bjh.17918
   PubMed Web of Science ®Google Scholar
• Attolico I, Tarantini F, Carluccio P, et al. Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. Br J Haematol. 2022;196(4):928–931. doi:10.1111/bjh.17873
   PubMed Web of Science ®Google Scholar
• Einarsdottir S, Martner A, Nicklasson M, et al. Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. Haematologica. 2022;107(6):1479–1482. doi:10.3324/haematol.2021.280494
   PubMed Web of Science ®Google Scholar
• Redjoul R, Le Bouter A, Parinet V, et al. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. Lancet Haematol. 2021;8(10):e681–e683. doi:10.1016/S2352-3026(21)00274-X
   PubMed Web of Science ®Google Scholar
• Muecksch F, Wang Z, Cho A, et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607(7917):128–134. doi:10.1038/s41586-022-04778-y
   PubMed Web of Science ®Google Scholar
• Piñana JL, Pérez A, Montoro J, et al. Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: a cross-sectional, prospective, observational study. Clin Infect Dis. 2019;68(11):1894–1903. doi:10.1093/cid/ciy792
   PubMed Web of Science ®Google Scholar
• Natori Y, Humar A, Lipton J, et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2017;52(7):1016–1021. doi:10.1038/bmt.2017.24
   PubMed Web of Science ®Google Scholar
• NCCN. COVID-19 resources [Internet]. National Comprehensive Cancer Network [Cited 2022] Available from https://www.nccn.org/covid-19.
   Google Scholar
• BMTCTN. CIBMTR SC21-07/blood and marrow transplant clinical trials network (bmt ctn) 2101 covid observational study materials [Internet]. [Cited 2022] Available from: https://web.emmes.com/study/bmt2/protocol/2101_protocol/2101_protocol.html.
   Google Scholar